TRAX vs TVGN

First Tracks Biotherapeutics, I vs Tevogen Bio Holdings Inc. — Valuation Comparison 2026

TRAX

Biotechnology
First Tracks Biotherapeutics, I
Quality
1.7
out of 10
Value Trap
Price
$15.82
Last close
Models
7/13
Active
VS

TVGN

Biotechnology
Tevogen Bio Holdings Inc.
Quality
3.0
out of 10
Value Trap
24
SAFE
Price
$8.04
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TRAX Fair ValueTRAX Upside TVGN Fair ValueTVGN Upside
Bayesian DCF Intrinsic $4.19 -73.5% $1.95 -75.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.69 -77.1% $0.41 -94.9%
PWERM Option-Based $7.49 -53.6% $10.74 +33.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRAX vs TVGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRAX vs TVGN — Which Stock Is More Undervalued?

TVGN scores higher with a 3.0/10 quality rating vs TRAX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing First Tracks Biotherapeutics, I (TRAX) and Tevogen Bio Holdings Inc. (TVGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRAX currently trades at $15.82 with a QOC of 1.7/10, while TVGN trades at $8.04 with a QOC of 3.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).